| Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab E Orfanoudaki, M Gazouli, K Foteinogiannopoulou, E Theodoraki, ... European Journal of Gastroenterology & Hepatology 31 (2), 187-191, 2019 | 13 | 2019 |
| Asymptomatic hyperCKemia during infliximab therapy in patients with inflammatory bowel disease E Theodoraki, E Orfanoudaki, K Foteinogiannopoulou, IE Koutroubakis Inflammatory Bowel Diseases 24 (6), 1266-1271, 2018 | 8 | 2018 |
| Primary hypogammaglobulinaemia with inflammatory bowel disease-like features: an ECCO CONFER multicentre case series A Albshesh, P Eder, DG Ribaldone, B Oldenburg, NK de Boer, ... Journal of Crohn's and Colitis 16 (1), 91-97, 2022 | 6 | 2022 |
| Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease? E Theodoraki, E Orfanoudaki, K Foteinogiannopoulou, E Legaki, ... Intestinal research 19 (4), 461, 2021 | 6 | 2021 |
| Pembrolizumab-induced antiTTG IgA-negative duodenitis treated with gluten withdrawal E Theodoraki, M Giannarakis, M Tzardi, IΕ Koutroubakis European Journal of Gastroenterology & Hepatology 33 (8), 1130-1131, 2021 | 3 | 2021 |
| First case of Whipple’s disease successfully treated with tigecycline K Foteinogiannopoulou, I Mouzas, M Tzardi, E Orfanoudaki, E Theodoraki, ... Germs 11 (1), 105, 2021 | 3 | 2021 |
| Real-life utility and diagnostic accuracy of a home-performed fecal calprotectin test to predict endoscopic activity in patients with inflammatory bowel disease under … E Orfanoudaki, I Drygiannakis, E Theodoraki, K Foteinogiannopoulou, ... European Journal of Gastroenterology & Hepatology 33 (1S), e777-e782, 2021 | 2 | 2021 |
| New-onset severe hypercholesterolemia in a patient with cholestatic liver disease. Should we treat the lipids? P Papakonstantinou, E Theodoraki, M Koulentaki, J Papadakis Atherosclerosis 263, e253-e254, 2017 | 2 | 2017 |
| Active smoking is associated with the development of adverse events of biological therapy in patients with inflammatory bowel disease E Theodoraki, E Orfanoudaki, E Petroulaki, K Foteinogiannopoulou, ... European Journal of Gastroenterology & Hepatology 35 (1), 15-20, 2023 | 1 | 2023 |
| Crohn’s Disease-Like Features in a Patient With IgE and Selective IgG1 and IgG3 Deficiency I Drygiannakis, E Theodoraki, M Tsafaridou, I Koutroubakis Cureus 15 (2), 2023 | | 2023 |
| Correction to: Effect of antinuclear antibodies on pharmacokinetics of anti‑TNF therapy in patients with inflammatory bowel disease E Theodoraki, E Orfanoudaki, K Foteinogiannopoulou, NP Andreou, ... International Journal of Colorectal Disease 37 (3), 647-648, 2022 | | 2022 |
| P339 Effect of antinuclear antibodies on pharmacokinetics of anti-TNF therapy in patients with Inflammatory Bowel Disease E Theodoraki MD-MA-PhD c, E Orfanoudaki, K Foteinogiannopoulou, ... Journal of Crohn's and Colitis 16 (Supplement_1), i354-i355, 2022 | | 2022 |
| Clinical Value of Proactive Infliximab Drug Monitoring in Patients With Inflammatory Bowel Disease E Orfanoudaki, K Foteinogiannopoulou, E Theodoraki, IE Koutroubakis Inflammatory Bowel Diseases 26 (6), e50-e50, 2020 | | 2020 |
| Case Report New-onset severe hypercholesterolemia in a patient with cholestatic liver disease. Should we treat the lipids? PE Papakonstantinou, E Theodoraki, M Koulentaki, JA Papadakis, ... | | 2016 |
